Myasthenia gravis is a chronic autoimmune disorder that disrupts nerve-to-muscle signaling, causing weakness. Modern treatments help many people live typical life spans and enter remission.

Approximately 70 to 300 million individuals worldwide are living with myasthenia gravis, an antibody-mediated autoimmune disorder that adversely affects neuromuscular junction function. “Research has ...

Myasthenia gravis (MG) is sometimes referred to as the “snowflake disease” because no two people with MG are ever alike. This is also true for treatment response. Like other autoimmune diseases, there ...

Please provide your email address to receive an email when new articles are posted on . Those treated with Uplizna showed greater improvement on all myasthenia gravis metrics vs. placebo. Safety ...

After years of a therapeutic drought in generalized myasthenia gravis (gMG), new targeted therapies are finally providing options for rapidly effective and safe treatment. This rare autoimmune ...

Efgartigimod shows promising early response in generalized myasthenia gravis, especially in patients with short disease duration and severe bulbar symptoms. New guidelines and advocacy enhance ...

Biologics License Application acceptance supported by results from the Phase 3 Vivacity-MG3 study Results demonstrate sustained disease control over 24 weeks in a broad population of antibody positive ...

Snowflake disease is no laughing matter. While the term “snowflake” has been used to mock a fragile person who melts easily, ...

A study based on the EXPLORE-MG registry reveals that African-American and Hispanic patients tend to develop myasthenia gravis (MG) at younger ages and experience more-severe symptoms, including ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. The first patient has been dosed in a phase 3 clinical ...